Form 4: Theravance Biopharma Exec's Routine Tax Share Withholding

Theravance Biopharma's SVP, General Counsel, and Secretary, Brett A. Grimaud, reported a routine disposition of shares to cover tax obligations from vested restricted stock units.

Summary

• Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc. (TBPH), reported a transaction.
• 20,833 Ordinary Shares were disposed of on February 20, 2026.
• The shares were withheld by the issuer at a price of $19.66 per share to satisfy tax obligations.
• This transaction resulted from the vesting of previously granted restricted stock units and was not an open market sale.
• Following this transaction, Grimaud beneficially owns 334,449 Ordinary Shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative transaction for tax purposes rather than a discretionary sale or purchase by an insider.

Positives

• The transaction is a routine event related to compensation, indicating the vesting of previously granted equity awards.

Negatives

• A reduction in direct share ownership by a key executive, although for tax purposes.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholdings from vested equity awards, are common occurrences in the biotechnology and pharmaceutical industries. These events are typically routine and do not reflect a change in management's outlook or a strategic shift, unlike open market sales or purchases.

Comparison to Industry Standards

• This type of share withholding for tax purposes is a standard practice across publicly traded companies, including those in the biotech sector like Amgen or Gilead Sciences, where executive compensation often includes restricted stock units. It aligns with typical compensation and tax management practices for executives receiving equity awards.

Related Party Transactions

• The share withholding transaction was conducted with the issuer (Theravance Biopharma, Inc.) to satisfy tax obligations, which constitutes a related party transaction, though it is a standard administrative process for equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine tax-related transaction by an executive, not indicative of a change in company fundamentals or strategy.
• No direct impact on employees, customers, suppliers, or creditors is implied by this filing.

Key Dates

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Transaction, Share Withholding, Restricted Stock Units, Tax Obligation, Executive Compensation, Brett A. Grimaud